PAVmed Inc. Reports Q2 2025 Results: Revenue at $1.2 Million, GAAP Net Loss of $13.3 Million, EPS at $(0.74); Adjusted Loss at $1.8 Million, EPS at $(0.11)

<a href="https://laohu8.com/S/PAVM">PAVmed Inc.</a> Reports <a href="https://laohu8.com/S/QTWO">Q2</a> 2025 Results: Revenue at $1.2 Million, GAAP Net Loss of $13.3 Million, EPS at $(0.74); Adjusted Loss at $1.8 Million, EPS at $(0.11)

PAVmed Inc., a diversified commercial-stage medical technology company, reported financial results for the second quarter of 2025. Lucid Diagnostics Inc., a subsidiary of PAVmed, processed 2,756 EsoGuard tests during the quarter, generating $1.2 million in revenue. This marks a significant milestone for the company as it pushes forward with its strategic goals. Additionally, Lucid has secured a meeting on September 4 to discuss Medicare Local Coverage Determination for EsoGuard. Veris Health Inc., another PAVmed subsidiary, completed its second-quarter financing, which allowed it to relaunch the development of its implantable physiological monitor. Veris is taking integration steps to commence the commercial phase in partnership with OSU-The James. These developments reflect PAVmed's strategy to stabilize its corporate structure and strengthen its balance sheet, positioning it as a diversified commercial life sciences entity with multiple independently-financed subsidiaries operating under a shared services model.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. PAVmed Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001641172-25-023729), on August 14, 2025, and is solely responsible for the information contained therein.

免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。

老虎证券

PAVmed Inc. Reports Q2 2025 Results: Revenue at $1.2 Million, GAAP Net Loss of $13.3 Million, EPS at $(0.74); Adjusted Loss at $1.8 Million, EPS at $(0.11)

热议股票